C Better Daily
C Better Daily
C Better Daily
C Better Daily
C Better Daily

C Better Daily

$29.99$49.99

C Better Daily | CBD Eye Drops | MAX N-Acetyl-Carnosine | 30mg-100mg

Results from trials using N-Acetyl-Carnosine confirmed accelerated healing ofcorneal erosions, trophic keratitis, post-herpetic epitheliopathy, primary and secondary corneal dystrophy, bullous keratopathy, and eliminate existing cataracts.

 

Clear
Compare

Product Description

C Better Daily | CBD Eye Drops | MAX N-Acetyl-Carnosine | 30mg-100mg

Introducing the first Cannabidiol (CBD) product on the global market specifically formulated to deliver CBD at a cellular level to the eye.

C Better Daily ™ penetrates the cornea and retina, bringing CBD holistically to the source of glaucoma, cataracts, degenerative eye disease, allergies and dry eye.

C Better Daily™ offers a harmonic blend of herbal extracts that have been used as holistic remedies for centuries. These herbs have been chosen for their specific abilities to reduce swelling, itching and inflammation. Eyebright is specifically beneficial for many eye problems including severe inflammation of the eye, inflammation of the eyelids, conjunctivitis, cataracts, stye, weeping eye, and bloodshot or strained eyes.

The first eye drop of its kind, C Better Daily™ is formulated with full plant micro encapsulated CBD that is extracted using supercritical CO2. Engineered at 300 nano meters, C Better Daily™ can penetrate through every level of the eye, including the optic nerve. The result, C Better Daily™ delivers CBD directly to the source of glaucoma and cataracts.

N-Acetyl-Carnosine, a key ingredient in C Better Daily™, has demonstrated efficacy in treating a variety of ophthalmic conditions, including corneal diseases, cataracts, glaucoma, and increased intraocular pressure. Results from trials using N-Acetyl-Carnosine confirmed accelerated healing ofcorneal erosions, trophic keratitis, post-herpetic epitheliopathy, primary and secondary corneal dystrophy, and bullous keratopathy. Most striking, however, was the ability of carnosine to eliminate existing cataracts.

C Better Daily™ offers a harmonic blend of herbal extracts that have been used as holistic remedies for centuries. These herbs have been chosen for their specific abilities to reduce swelling, itching and inflammation. Eyebright is specifically beneficial for many eye problems including severe inflammation of the eye, inflammation of the eyelids, conjunctivitis, cataracts, stye, weeping eye, and bloodshot or strained eyes.

PubMed
US National Library of Medicine National Institutes of Health
ABSTRACT
Drugs R D. 2002;3(2):87-103.
Efficacy of N-acetylcarnosine in the treatment of cataracts.
Contributing: Babizhayev MA1, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, Zhukotskii AV, Goldman IM.

PURPOSE:
To evaluate the effects of 1% N-acetylcarnosine (NAC) solution on lens clarity over 6 and 24 months in patients with cataracts.

TRIAL DESIGN:
Randomised, placebo-controlled study.

PARTICIPANTS:
49 subjects (76 affected eyes) with an average age of 65.3 +/- 7.0 years with a diagnosis of senile cataract with minimum to advanced opacification in various lens layers.

METHODS:
26 patients (41 eyes) were allocated to topical NAC 1% eyedrops twice daily. The control group consisted of 13 patients (21 eyes) who received placebo eyedrops and 10 patients (14 eyes) who did not receive eyedrops.

MAIN OUTCOME MEASURES:
All patients were evaluated at entry and followed up every 2 months for a 6-month period (trial 1), or at 6-month intervals for a 2-year period (trial 2), for best-corrected visual acuity and glare testing. In addition, cataract was measured using stereocinematographic slit-images and retro-illumination examination of the lens. Digital analysis of lens images displayed light scattering and absorbing centres in two- and three-dimensional scales.

RESULTS:
The overall intra-reader reproducibility of cataract measurements (image analysis) was 0.830, and glare testing 0.998. After 6 months, 90% of NAC-treated eyes showed improvement in best corrected visual acuity (7 to 100%) and 88.9% showed a 27 to 100% improvement in glare sensitivity. Topographic studies indicated fewer areas of posterior subcapsular lens opacity and 41.5% of treated eyes had improvement in image analysis characteristics. The overall ratios of image analysis characteristics at 6 months compared with baseline measures were 1.04 and 0.86 for the control and NAC-treated group, respectively (p < 0.001). The apparent benefits of treatment were sustained after 24 months' treatment. No treated eyes demonstrated worsening of vision. The overall visual outcome in the control group showed significant worsening after 24 months in comparison with both baseline and the 6-month follow-up examination. The overall clinical results observed in the NAC-treated group by the 24-month period of examination differed significantly (p < 0.001) from the control group in the eyes with cortical, posterior subcapsular, nuclear or combined lens opacities. Tolerability of NAC eyedrops was good in almost all patients, with no reports of ocular or systemic adverse effects.

CONCLUSION:
Topical NAC shows potential for the treatment and prevention of cataracts.
PMID: 12001824

Reference
Babizhayev, M.A., (2002). Efficacy of N-acetylcarnosine in the treatment of cataracts retrieved online from PubMed.gov on 03/24/18 at https://www.ncbi.nlm.nih.gov/pubmed/12001824 .

Additional Information

Choose

Adult MAX Strength 100mg, Adult Strength 50mg, Children Strength 30mg, Pet Strength 40mg

Reviews

There are no reviews yet.

Be the first to review “C Better Daily”

Your email address will not be published. Required fields are marked *